NTRK1 and neoplasm: In these cases, BRAF alterations function as tumor-agnostic predictive biomarkers, similar to NTRK1, NTRK2, and NTRK3 (NTRK1-3) gene fusions, supporting the rationale for broad molecular profiling and precision targeting strategies in rare GI tumors [12].